NCI’s Office of Cancer Nanotechnology Research has published a new funding opportunity announcement (FOA) for the Innovative Research in Cancer Nanotechnology (IRCN) initiative...
Nanotechnology Characterization Lab
Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoparticles.
The NCL serves as a national resource and knowledge base for all cancer researchers to facilitate the regulatory review of nanotechnologies intended for cancer therapies and diagnostics. By providing the critical infrastructure and characterization services to nanomaterial providers, the NCL accelerates the transition of basic nanoscale particles and devices into clinical applications, thereby reducing suffering and death from cancer.
There are multiple ways the NCL can help nanotech researchers and developers advance their technology, including characterization, reformulation, optimization, lead selection, method development, and more.
News & Updates
Not sure what the NCL does or how we might work together? Watch the NCL’s overview video to learn more about the services we offer.
Missed the NYAS meeting on “Equivalence of Complex Drug Products: Scientific and Regulatory Challenges”?
Meet Us @
The USP workshop on computer modeling offer case studies for discussion where a computer modeling/simulation tool was used to evaluate data collected from dissolution,...
The American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition takes place in San Diego, CA, November 12-15th.
- ‹ previous
- 2 of 2